Subsequently, there was a significant lull in the development of tumor immunotherapy until the breakthrough discoveries of anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) in 1987 [17] and anti-PD1 (programmed cell death protein 1) in 1992 [18]. The gene discussed is CTLA4; the disease is neoplasm.